hydroxyurea has been researched along with Malaria in 14 studies
Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, where the greatest sickle-cell burden exists, remain unknown." | 9.24 | Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. ( Hodges, JS; Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Ndugwa, CM; Opoka, RO; Ware, RE, 2017) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 7.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| "Splenomegaly is an unexplained risk factor for malaria infections among children with SCA in Africa." | 5.91 | Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. ( Aygun, B; Howard, TA; Lane, A; Latham, TS; McElhinney, K; Olupot-Olupot, P; Santos, B; Smart, LR; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2023) |
| "Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, where the greatest sickle-cell burden exists, remain unknown." | 5.24 | Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. ( Hodges, JS; Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Ndugwa, CM; Opoka, RO; Ware, RE, 2017) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 3.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| "Hydroxyurea has proven safety, feasibility, and efficacy in children with sickle cell anemia in sub-Saharan Africa, with studies showing a reduced incidence of vaso-occlusive events and reduced mortality." | 2.94 | Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. ( Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Nabaggala, C; Ndugwa, CM; Opoka, RO; Ware, RE, 2020) |
| "Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa." | 2.90 | Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. ( Aygun, B; Lane, A; Latham, TS; McGann, PT; Olupot-Olupot, P; Santos, B; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2019) |
| " The full enrollment to REACH confirms the feasibility of conducting high-quality SCA research in Africa; this study will provide vital information to guide safe and effective dosing of hydroxyurea for children with SCA living in Africa." | 2.87 | Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. ( Aygun, B; Howard, TA; Kitenge, R; Lane, A; Latham, T; Luís Reis da Fonseca, J; McElhinney, K; McGann, PT; Mochamah, G; Olupot-Olupot, P; Santos, B; Stuber, S; Tomlinson, GA; Tshilolo, L; Wabwire, H; Ware, RE; Williams, TN, 2018) |
| "Because malaria is thought to be a significant cause of morbidity and mortality in patients with SCD, malaria chemoprophylaxis is often recommended for these patients." | 2.49 | Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease. ( Aneni, EC; Gill, CJ; Hamer, DH, 2013) |
| "Splenomegaly is an unexplained risk factor for malaria infections among children with SCA in Africa." | 1.91 | Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. ( Aygun, B; Howard, TA; Lane, A; Latham, TS; McElhinney, K; Olupot-Olupot, P; Santos, B; Smart, LR; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2023) |
| " These data endorse broad, safe, and long-term use of HU for SCA in malaria-endemic countries and provide a novel biological model for the treatment of a genetic disorder with simultaneous, adjunct therapy of a life-threatening infection needed in a global health setting." | 1.91 | Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. ( Haldar, K; Mohandas, N; Safeukui, I; Ware, RE, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 7 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taylor, SM | 1 |
| Korwa, S | 1 |
| Wu, A | 1 |
| Green, CL | 1 |
| Freedman, B | 1 |
| Clapp, S | 1 |
| Kirui, JK | 1 |
| O'Meara, WP | 1 |
| Njuguna, FM | 1 |
| Olupot-Olupot, P | 3 |
| Tomlinson, G | 2 |
| Williams, TN | 3 |
| Tshilolo, L | 3 |
| Santos, B | 3 |
| Smart, LR | 1 |
| McElhinney, K | 2 |
| Howard, TA | 2 |
| Aygun, B | 3 |
| Stuber, SE | 2 |
| Lane, A | 5 |
| Latham, TS | 4 |
| Ware, RE | 6 |
| Odame, I | 2 |
| Safeukui, I | 1 |
| Mohandas, N | 1 |
| Haldar, K | 1 |
| Archer, NM | 1 |
| John, CC | 2 |
| Opoka, RO | 2 |
| Hume, HA | 2 |
| Nabaggala, C | 1 |
| Kasirye, P | 2 |
| Ndugwa, CM | 2 |
| Cavanaugh, R | 1 |
| Hodges, JS | 1 |
| McGann, PT | 2 |
| Tomlinson, GA | 1 |
| Luís Reis da Fonseca, J | 1 |
| Kitenge, R | 1 |
| Mochamah, G | 1 |
| Wabwire, H | 1 |
| Stuber, S | 1 |
| Latham, T | 1 |
| Chung, DW | 1 |
| Ponts, N | 1 |
| Prudhomme, J | 1 |
| Rodrigues, EM | 1 |
| Le Roch, KG | 1 |
| Aneni, EC | 1 |
| Hamer, DH | 1 |
| Gill, CJ | 1 |
| Hardeman, MR | 1 |
| Ince, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)[NCT03178643] | Phase 4 | 246 participants (Actual) | Interventional | 2018-01-23 | Completed | ||
| Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study[NCT03128515] | Phase 3 | 187 participants (Actual) | Interventional | 2017-07-26 | Completed | ||
| Novel Use Of Hydroxyurea in an African Region With Malaria[NCT01976416] | Phase 3 | 208 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA[NCT01966731] | Phase 1/Phase 2 | 635 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Malaria is defined as the presence of P. falciparum or P. malariae on the peripheral smear of any child brought in for medical evaluation of fever. P. vivax, P. ovale and P. knowlesi are not known to be present in this region, but if a child is seen with suspected infection with any of these malaria parasites, this will also be recorded as a case of malaria. Incidence will be reported in the number of cases per 100 patient years. (NCT01976416)
Timeframe: 12 months
| Intervention | malaria episodes (Number) |
|---|---|
| Hydroxyurea | 5 |
| Placebo | 7 |
An expected toxicity rate of 20% and acceptable toxicity rate of 30% were used for statistical calculations. After 53 participants at each site complete 3 months of therapy, if ≤ 15 participants have hematologic toxicity there is no early evidence against safety. If ≥ 15 of the initial participants experience toxicity, this is early evidence against safety. Future participants will begin at a lower dose of hydroxyurea (10 ± 2.5 mg/kg), with another 53 participants recruited of the same safety analysis. Upon final analysis of 133 participants at the same starting dose, safety for fixed-dose hydroxyurea can be concluded. (NCT01966731)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| Hydroxyurea | 5.1 |
1 review available for hydroxyurea and Malaria
| Article | Year |
|---|---|
Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antimalarials; Antisickling Agents; Comorbidity; Dr | 2013 |
5 trials available for hydroxyurea and Malaria
| Article | Year |
|---|---|
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemisinins; Chemoprevention; Child; Child, Presch | 2022 |
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Dose-Response Relationship, Drug; Double | 2020 |
Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Child, Preschool; Double-Blind Method; E | 2017 |
Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
Topics: Africa South of the Sahara; alpha-Thalassemia; Anemia, Sickle Cell; Blood Transfusion; Child; Child, | 2018 |
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dose- | 2019 |
8 other studies available for hydroxyurea and Malaria
| Article | Year |
|---|---|
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Incidence; Malaria; Spl | 2023 |
HU for SCA in Africa: associated malaria benefit.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Incidence; Malaria | 2023 |
Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia.
Topics: Anemia, Sickle Cell; Blood Transfusion; Erythrocytes; Humans; Hydroxyurea; Malaria; Malaria, Falcipa | 2023 |
Further evidence supporting the global use of hydroxyurea.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Malaria | 2023 |
Lucio Luzzatto: tackling blood disorders on multiple continents.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Bone Marrow Examination; Glucosephos | 2021 |
Hydroxyurea for SCA in Africa: no malaria harm.
Topics: Africa; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Malaria | 2017 |
Characterization of the ubiquitylating components of the human malaria parasite's protein degradation pathway.
Topics: Amino Acid Sequence; Endoplasmic Reticulum; Endoplasmic Reticulum-Associated Degradation; Host-Paras | 2012 |
Clinical potential of in vitro measured red cell deformability, a myth?
Topics: Adult; Age Factors; Anemia, Sickle Cell; Cell Count; Child, Preschool; Cyclosporine; Elliptocytosis, | 1999 |